insulin-like growth factor 2 | IGF-2

type II hypersensitivity reaction [ cytotoxic reaction | antibody-mediated hypersensitivity | cytolytic reaction ]

type II hypersensitivity reaction | cytotoxic reaction | antibody-mediated hypersensitivity | cytolytic reaction

Atrioventricular block, type I and II Möbitz block, type I and II Second-degree block, type I and II Wenckebach's block

EC-type examination certificate | EU-type examination certificate

Golgi type II neuron [ Golgi type II cell ]

type 2 diabetes mellitus [ type 2 diabetes | type II diabetes mellitus | type II diabetes | slow-onset diabetes mellitus | ketosis-resistant diabetes mellitus | stable diabetes mellitus | non-insulin-dependent diabetes mellitus | adult-onset diabetes | adult-onset diabetes mellitus | maturity-onset ]

Progressive bulbar palsy of childhood [Fazio-Londe] Spinal muscular atrophy:adult form | childhood form, type II | distal | juvenile form, type III [Kugelberg-Welander] | scapuloperoneal form

Anaemia:haemolytic nonspherocytic (hereditary), type II | hexokinase deficiency | pyruvate kinase [PK] deficiency | triose-phosphate isomerase deficiency

Human insulin was the first true biotechnology based product and gradually replaced the insulin extracted from cattle and pigs.

It is currently the most available form of insulin worldwide, accounting for 70% of the worldwide insulin market.

Question No. 53 Ms. Kirsty Duncan: With respect to the chronic cerebrospinal venous insufficiency (CCSVI) clinical trial being undertaken by Dr. Traboulse: (a) what milestones are reportable to the government, (i) on what date(s) is reporting expected to occur, (ii) how will this information be communicated to patients, the medical community, and the general public; (b) on what date did each of the trial sites pass ethical review; (c) on what date did recruitment of patients begin for each of the trial sites; (d) how many patients with multiple sclerosis (MS) are being recruited for each site, and how is consistency in diagnosis and t ...[+++]reatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) how is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with bo ...

Question No. 138 Hon. John McKay: With respect to Canadians with diabetes who suffer severe and life-threatening adverse reactions to synthetic insulin and are unable to obtain domestically, an alternative animal-based insulin: (a) what actions has Health Canada taken or will take to ensure that Canadians who require such medication will continue to have access to it; (b) is the government (i) investigating methods of producing the medication via public funds or public-private partnership, (ii) initiating a process seeking approval o ...[+++]f the drug for domestic production and distribution, (iii) initiating a consultation process with the manufacturers of animal insulin seeking domestic production and distribution, (iv) providing incentives to manufacturers to produce animal insulin domestically, (v) securing a guarantee from the manufacturer that the drug will be permanently available, (vi) stockpiling the medication to ensure near-term supply; (c) what has Health Canada done or what will it do to ensure that these Canadians receive financial assistance due to high costs as a result of provincial health insurance plans not covering certain medications or treatments; (d) what action has Health Canada taken or will take to ensure (i) that people who suffer negative effects from synthetic insulin are aware of and have access to proper treatment as well as expanded choice in treatment options, (ii) that medical professionals who are responsible for treating Canadians with diabetes are aware of the availability of alternative forms of medication such as beef and pork based insulin; (e) what action has Health Canada taken or will take to ascertain how many Canadians suffer adverse reactions from synthetic insulin; (f) has Health Canada investigated or will be investigating the implementation of a protocol to address this issue, if not, why have steps not been taken to address this issue; and (g) does the lack of the availability of this type of medically necessary treatme ...